Provided by Tiger Trade Technology Pte. Ltd.

Cogent Biosciences, Inc.

36.80
+0.57001.57%
Post-market: 37.000.2000+0.54%17:24 EDT
Volume:1.39M
Turnover:51.25M
Market Cap:6.39B
PE:-17.04
High:37.08
Open:36.56
Low:36.44
Close:36.23
52wk High:43.73
52wk Low:11.60
Shares:173.52M
Float Shares:166.83M
Volume Ratio:0.86
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1600
EPS(LYR):-2.5504
ROE:-109.74%
ROA:-43.84%
PB:13.66
PE(LYR):-14.43

Loading ...

Cogent says PEAK Phase 3 trial shows bezuclastinib-sunitinib combo extends PFS in second-line GIST

Reuters
·
May 30

Cogent Biosciences - Bezuclastinib Combination Demonstrates Statistically Significant Pfs Advantage in Gist Patients

THOMSON REUTERS
·
May 30

Cogent Biosciences Announces Detailed Clinical Data From Peak Phase 3 Trial With Bezuclastinib in Combination With Sunitinib in Gastrointestinal Stromal Tumors (Gist) at 2026 American Society of Clinical Oncology (Asco) Annual Meeting

THOMSON REUTERS
·
May 30

BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's

Reuters
·
May 29

Cogent Biosciences announces FDA acceptance of bezuclastinib NDA

TIPRANKS
·
May 28

BUZZ-Cogent rises as US FDA accepts marketing application for cancer drug

Reuters
·
May 28

Cogent says FDA accepts bezuclastinib-sunitinib NDA for GIST, grants priority review

Reuters
·
May 28

Cogent Biosciences - FDA Does Not Plan Advisory Committee or Identify Review Issues for Nda

THOMSON REUTERS
·
May 28

Cogent Biosciences - FDA Grants Priority Review to Nda With Pdufa Date November 30, 2026

THOMSON REUTERS
·
May 28

Cogent Biosciences Announces FDA Acceptance of New Drug Application (Nda) With Priority Review for Bezuclastinib in Combination With Sunitinib for Patients With Gist

THOMSON REUTERS
·
May 28

Cogent Biosciences to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

Cogent Biosciences (COGT) Receives a Rating Update from a Top Analyst

TIPRANKS
·
May 10

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO), OnKure Therapeutics (OKUR) and Cogent Biosciences (COGT)

TIPRANKS
·
May 06

Guggenheim Sticks to Their Buy Rating for Cogent Biosciences (COGT)

TIPRANKS
·
May 06

Analysts Offer Insights on Healthcare Companies: Orthofix Medical (OFIX), BioNTech SE (BNTX) and Cogent Biosciences (COGT)

TIPRANKS
·
May 06

Cogent Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Cogent Q1 net loss widens 35.28% to $97.4 million

Reuters
·
May 05

BRIEF-Cogent Biosciences Q1 Income From Operations USD -103.607 Million

Reuters
·
May 05

Cogent Biosciences Inc - Ended 1Q 2026 With $866.4 Mln in Cash, Sufficient to Fund Operations Into 2028

THOMSON REUTERS
·
May 05

Cogent Biosciences Q1 Net Income USD -97.352 Million

THOMSON REUTERS
·
May 05